Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575401 | 1.00 | MEN1 (0.58) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3591495 | 0.90 | LMNA (0.53) | MEN1KMT2ALMNAPOLBOXTR | |
| SCHEMBL3578863 | 0.86 | KMT2A (0.55) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3581757 | 0.86 | KMT2A (0.55) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3580411 | 0.82 | KMT2A (0.57) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3585948 | 0.82 | KMT2A (0.57) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3588172 | 0.82 | RBP4 (0.67) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL3579174 | 0.79 | KMT2A (0.56) | MEN1KMT2ALMNAPOLBDRD2 | |
| SCHEMBL13518961 | 0.77 | HCRTR1 (0.58) | MEN1KMT2APOLBDRD2ALDH1A1 | |
| SCHEMBL3591355 | 0.77 | TGFBR1 (0.59) | MEN1KMT2ALMNADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075953-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIAZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | HRH3, HRH4, HRH2 | MEN1 1222/4885KMT2A 209/4885LMNA 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.